Astex Pharmaceuticals to Present at Piper Jaffray Health Care Conference on November 29th

DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, and Mohammad Azab, M.D., chief medical officer, will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29th in New York.

The Company's presentation will begin at 8:10 a.m. ET. A live webcast of the presentation will be available in the Investor Events section of the Company's website, www.astx.com. The webcast will be archived for 30 days.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals, formerly SuperGen, developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.



CONTACT:

Astex Pharmaceuticals, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Marketing
[email protected]
Susanna Chau, 925-560-2845
Manager
Investor Relations
[email protected]
or
The Trout Group
Alan Roemer, 646-378-2945
Managing Director
[email protected]
or
College Hill
Melanie Toyne-Sewell, +44 20 7866 7866 (Europe)
Rebecca Skye Dietrich, 857-241-0795 (US)
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.